Shanghai RAAS shareholders approve profit distribution, governance changes

Shanghai RAAS Blood Products Co., Ltd. announced the resolutions from its third extraordinary general meeting of shareholders held on December 15, 2025. The meeting, presided over by vice chairman and general manager Jun Xu, saw 49.8286% of total voting shares represented, with 3.27bn shares in attendance. Notably, 841 small and medium-sized shareholders, representing 12.2976% of voting shares, participated.

A key resolution passed was the "2025 First Three Quarters Profit Distribution Plan," approved with 3.25bn votes (99.4538% of attending shareholders' effective voting shares). Shareholders also approved revisions to the company's Articles of Association and Shareholder Meeting Rules, both by special resolution, achieving more than three-quarters majority. The former received 3.18bn votes (97.3623%) while the latter secured 3.25bn votes (99.4459%).

Additionally, the meeting approved revisions to the Board of Directors Meeting Rules, Independent Director Work System, Related Party Transaction Management Measures, External Guarantee Management Measures, Director Remuneration and Assessment System, and Fundraising Management Measures. The "Future Three-Year (2024-2026) Shareholder Return Plan" also passed as a special resolution, with 3.25bn votes (99.4599%). Two new directors, a non-independent and an independent, were also elected.